Clinical Observation of Regorafenib Combined with Immune Checkpoint Inhibitor for Advanced Colorectal Cancer of pMMR/MSS Type

• DOI: 10.26689/otd.v2i2.7408
• Publication Date: 2024-07-18T08:34:03Z
• Authors: Zhe Shi; Liyuan Zhou; Guodong Zhao
• Keywords: Regorafenib; Immune checkpoint

Objective: To observe the clinical efficacy and safety of regorafenib combined with immune checkpoint inhibitors in treatment patients advanced colorectal cancer pMMR/MSS type. Methods: 42 type admitted to Department Oncology our hospital from January 2022 September 2023 were randomly divided into observation group control group, 21 cases each. The was treated addition inhibitors, while given monotherapy, efficacy, adverse effects, survival two groups observed. Results: total remission rate 23.81%, 57.14%, difference between statistically significant (P < 0.05); there 14 reactions groups, an incidence 33.33% (14/42); overall 71.43% 47.62%, respectively. higher than that but not > 0.05). Conclusion: Regorafenib anti-PD-1 monoclonal antibody can significantly improve prognosis without increasing effects.